Physician profile
Benjamin J Hirsh
NPI 1548586712
$53,435.43
in general payments reported to CMS, 2019-2025
11 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.97 · 2020: $109 · 2021: $6,600 · 2022: $4,000 · 2023: $6,936 · 2024: $14K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $841 · Travel and Lodging: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,152.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,401.00 |
| Food and Beverage | $841.25 |
| Travel and Lodging | $306.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15,742.94 | 2023-2025 | Vascepa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,259.07 | 2020-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8,016.43 | 2021-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $7,958.87 | 2025 | |
| Pfizer INC. | $3,600.00 | 2025 | |
| Lilly USA, LLC | $3,500.00 | 2024 | Mounjaro |
| Regeneron Healthcare Solutions, INC. | $2,500.00 | 2021 | |
| Amgen INC. | $1,401.00 | 2025 | Repatha |
| Zoll Medical Corporation | $432.15 | 2023 | |
| Novartis Pharmaceuticals Corporation | $24.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Hirsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.